Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats - PubMed (original) (raw)
Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats
N Nagano et al. Kidney Int. 2006 Feb.
Free article
Abstract
Phosphorus directly controls parathyroid hormone (PTH) synthesis and secretion. Serum levels of the novel phosphate-regulating hormone, fibroblast growth factor 23 (FGF23), are positively correlated with hyperphosphatemia in patients with chronic renal insufficiency (CRI). We proposed that changes in serum PTH and FGF23 levels might be associated with changes in serum phosphorus levels caused by the phosphate binder sevelamer hydrochloride (sevelamer, i.e. crosslinked poly[allylamine hydrochloride]). Rats were fed a diet containing adenine for 4 weeks to establish CRI. Animals were then offered either a normal diet or a diet containing 1 or 3% sevelamer for 8 weeks continuously, or intermittently with sevelamer diet or a normal diet offered for alternating 2-week periods. Changes in the serum levels of phosphorus, calcium, PTH, FGF23, and 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) were monitored over time. Adenine-treated rats developed severe CRI, with markedly elevated serum levels of phosphorus, PTH and FGF23, and reduced levels of serum 1,25(OH)(2)D(3). Continuous treatment with sevelamer suppressed these increases throughout the study period. Serum phosphorus, PTH, and FGF23 levels decreased rapidly when sevelamer treatments commenced and recovered rapidly once they were discontinued. However, the changes in serum FGF23 levels began after the onset of changes in serum phosphorus and PTH levels. In conclusion, circulating PTH, and FGF23 levels can be promptly manipulated through the control of serum phosphorus levels. Moreover, phosphate-binder treatment can effectively inhibit the elevation of serum FGF23 levels, as well as PTH levels, under conditions of CRI.
Comment in
- Fibroblast growth factor 23: the making of a hormone.
Schiavi SC. Schiavi SC. Kidney Int. 2006 Feb;69(3):425-7. doi: 10.1038/sj.ki.5000168. Kidney Int. 2006. PMID: 16514426
Similar articles
- [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M. Nagano N, et al. Clin Calcium. 2005 Sep;15 Suppl 1:35-9; discussion 39-40. Clin Calcium. 2005. PMID: 16272627 Japanese. - Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency.
Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M. Nagano N, et al. Nephrol Dial Transplant. 2006 Mar;21(3):634-43. doi: 10.1093/ndt/gfi137. Epub 2005 Sep 16. Nephrol Dial Transplant. 2006. PMID: 16169864 - Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.
Nagano N, Miyata S, Obana S, Ozai M, Kobayashi N, Fukushima N, Burke SK, Wada M. Nagano N, et al. Nephrol Dial Transplant. 2001 Sep;16(9):1870-8. doi: 10.1093/ndt/16.9.1870. Nephrol Dial Transplant. 2001. PMID: 11522872 - Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Koizumi M, Komaba H, Fukagawa M. Koizumi M, et al. Contrib Nephrol. 2013;180:110-23. doi: 10.1159/000346791. Epub 2013 May 3. Contrib Nephrol. 2013. PMID: 23652554 Review.
Cited by
- Chemical evidence for the tradeoff-in-the-nephron hypothesis to explain secondary hyperparathyroidism.
Phelps KR, Gemoets DE, May PM. Phelps KR, et al. PLoS One. 2022 Aug 1;17(8):e0272380. doi: 10.1371/journal.pone.0272380. eCollection 2022. PLoS One. 2022. PMID: 35913960 Free PMC article. - EOS789, pan-phosphate transporter inhibitor, ameliorates the progression of kidney injury in anti-GBM-induced glomerulonephritis rats.
Tsuboi Y, Ichida Y, Murai A, Maeda A, Iida M, Kato A, Ohtomo S, Horiba N. Tsuboi Y, et al. Pharmacol Res Perspect. 2022 Jun;10(3):e00973. doi: 10.1002/prp2.973. Pharmacol Res Perspect. 2022. PMID: 35621227 Free PMC article. - Effects of pharmacological inhibition of the sodium-dependent phosphate cotransporter 2b (NPT2b) on intestinal phosphate absorption in mouse and rat models.
Wang X, Xu Y, Yu X, Dey A, Zhang HY, Zink CM, Wodka D, Porter G, Matter WF, Porras L, Reidy CA, Peterson JA, Mattioni BE, Haas JV, Kowala MC, Wetterau JR. Wang X, et al. Pharmacol Res Perspect. 2022 Apr;10(2):e00938. doi: 10.1002/prp2.938. Pharmacol Res Perspect. 2022. PMID: 35194979 Free PMC article. - Endocrine Fibroblast Growth Factors in Relation to Stress Signaling.
Shimizu M, Sato R. Shimizu M, et al. Cells. 2022 Feb 1;11(3):505. doi: 10.3390/cells11030505. Cells. 2022. PMID: 35159314 Free PMC article. Review. - Threshold for Relationship between Vitamin D and Parathyroid Hormone in Chinese Women of Childbearing Age.
Hu Y, Li S, Wang J, Zheng D, Zhang H, Yu W, Zhu L, Liu Z, Yang X, Yang L. Hu Y, et al. Int J Environ Res Public Health. 2021 Dec 10;18(24):13060. doi: 10.3390/ijerph182413060. Int J Environ Res Public Health. 2021. PMID: 34948669 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical